BioCentury on BioBusiness,
Emerging Company Profile
ImmuNext developing VISTA antagonists, agonists for cancer, autoimmune diseases
Related tables, figures and sidebars
ImmuNext: New VISTAs
Monday, November 5, 2012
Inc. has developed an antagonist of VISTA, a ligand that negatively
regulates T cells similar to better known members of the B7 family of proteins.
But targeting VISTA could be safer than targeting other B7 proteins because it
may not lead to the severe immune responses seen with more widely expressed
members of the family.
Last month, ImmuNext granted Johnson
& Johnson exclusive, worldwide rights to develop and commercialize
products that antagonize VISTA - V-region immunoglobulin-containing suppressor
of T cell activation - a newly identified negative checkpoint regulator that is
a part of the B7 family. J&J plans to develop immunotherapies targeting
VISTA to treat cancer.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]